ANTH (ANTH) Stock Price & Analysis
ANTH (ANTH) rose 0.00% to USD 0 as of July 25, 2026 at 05:47 UTC, according to Nexqual real-time market data.
ANTH last closed at USD 0; the session ranged USD 0–0 on volume of 23,894 shares. Market capitalization is $2,617, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, July 25, 2026 at 05:47 UTC.
Key Statistics (as of July 25, 2026 at 05:47 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 23,894 shares |
| Market Cap | $2,617 |
| Exchange | PNK |
Technical Analysis (ANTH)
Nexqual's technical model rates ANTH "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of July 25, 2026 at 05:47 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 0 (oversold) |
| vs SMA50 | Below (USD 0) |
| MACD | -0 (negative) |
Analyst Ratings (ANTH)
Wall Street analysts rate ANTH "None", per Nexqual as of July 25, 2026 at 05:47 UTC.
| Consensus Rating | None |
|---|
Earnings (ANTH)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2018-03-31 | USD -0.42 vs est -0.54 ▲ beat |
| 2017-12-31 | USD -0.7 vs est -0.68 ▼ miss |
| 2017-09-30 | USD -0.73 vs est -0.9 ▲ beat |
| 2017-06-30 | USD -0.86 vs est -1.63 ▲ beat |
Source: Nexqual, July 25, 2026 at 05:47 UTC.
Financials & Fundamentals (ANTH)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -568.85% |
| Current Ratio | 3.3 |
| Total Cash | $8.09M |
| Total Debt | $0 |
| Free Cash Flow | $-17.92M |
Source: Nexqual, July 25, 2026 at 05:47 UTC.
Financial Health Score (ANTH)
Nexqual rates ANTH's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 05:47 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $8M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$32M |
| Efficiency | Critical — ROE -569%, ROA -142.0% |
Ownership (ANTH)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 26.18M |
| Float | 26.13M |
| Short % of Float | +8.41% |
Source: Nexqual, July 25, 2026 at 05:47 UTC.
Leadership (ANTH)
ANTH is led by Paul F. Truex (age 56), Executive Chairman, per Nexqual as of July 25, 2026 at 05:47 UTC.
| Executive Chairman | Paul F. Truex (age 56) |
|---|---|
| Senior Vice President of Global Regulatory Affairs and Compliance | Paul Adams (age 62) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IMUC | EOM Pharmaceutical Holdings Inc | USD 0.21 | ▼ 15.73% |
| BSPM | Biostar Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
| BGMSP | Bio Green Med Solution Inc. | USD 3.5 | ▲ 0% |
| AMPE | Ampio Pharmaceuticals, Inc. | USD 0.18 | ▲ 0% |
| ACUR | ACURA PHARMACEUTICALS INC | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:47 UTC. This page is informational and not investment advice.